SA-13353 is a TRPV1 agonist with cardioprotective effect. SA-13353 can be used for the research of cardiovascular disease .

ABT-116 is an orally active antagonist of transient receptor potential vanilloid type 1 (TRPV1). ABT-116 has analgesic efficacy. ABT-116 can be used for the research of neurological disease.

SAR-115740 is a TRPV1 antagonist. SAR-115740 exhibits developmental toxicity in H9 cell experiments. SAR-115740 can be used for research on inflammatory conditions or neurological disorders.

WYE-103914 is an orally active α7 nAChR (EC50 = 0.49 µM for rat α7 nAChR, EC50 = 0.57 µM for human α7 nAChR) agonist. WYE-103914 exhibits the ability to enhance memory in multiple cognitive models. WYE-103914 is used in combination with antipsychotic drugs. WYE-103914 can be used for research on schizophrenia.

SK2220691 is a potent TRPV4 inhibitor. SK2220691 inhibits pulmonary edema induced by GSK1016790. SK2220691 inhibits HCl-induced increases in key factors such as VEGF, keratinocyte-derived chemokine (KC; CXCL1), and granulocyte colony-stimulating factor (GCSF).

HDZI 2,4OH exerts significant anti anxiety activity through GABA receptors. HDZI 2,4OH can penetrate the blood-brain barrier. HDZI 2,4OH exhibits low toxicity in zebrafish. HDZI 2,4OH can be used for research on neurological disorders such as anxiety disorders.

AHN 070 is an irreversible peripheral benzodiazepine receptor (PBR) ligand. AHN 070 can bind to PBR with nanomolar affinity and is pH-dependent. AHN 070 can be used for studying the structure and function of PBR.

NVP-QBE170 is a selective Epithelial sodium channel (ENaC) inhibitor with an IC50 of 57.5 nM. NVP-QBE170 potently inhibits ENaC function in HBECs and shows a longer duration of action. NVP-QBE170 significantly attenuates ENaC activity in the airways of guinea pig models. NVP-QBE170 can be used for hyperkalaemia research.

VU6032735 is a potent and subtype-selective sperm-specific potassium channel 3 (SLO3) inhibitor with IC50 values of 165 nM (hSLO3) and 730 nM (mSLO3). VU6032735 also inhibits sodium channel and L-type calcium channel VU6032735 can sustain high tissue exposure in the fertilized oviduct. VU6032735 can be used for the research of contraception.

ZA18 is a selective TRPM2 channel inhibitor, with an IC50 value of 6.2 μM. ZA18 can effectively suppress intracellular Ca2+ overload triggered by TRPM2 channel activation. ZA18 significantly reduce the mortality of SH-SY5Y cells induced by H2O2. ZA18 can be used for the study of ischemia-reperfusion injury, inflammation, or other neurodegenerative diseases.

MBL-II-141 is potent ABCG2 inhibitor with an IC50 of 0.11 μM. MBL-II-141 inhibits the transport function of ABCG2 in a non-competitive manner, preventing ABCG2 from pumping substrates (such as Irinotecan) out of the cells, thereby increasing the accumulation of drugs within the cells. MBL-II-141 has no effect on ABCB1 (P-gp) and ABCC1 (MRP1) and has extremely low cytotoxicity (IG50 > 100 μM). MBL-II-141 can be used for the study of multidrug resistance (MDR) cancers.

SL-870495 is a calcium antagonist targeting L-type calcium channels. SL-870495 is promising for research of cardiovascular diseases such as hypertension and angina pectoris.

HM12 is a covalent inhibitor of L-/T-type calcium channels. HM12 can strongly inhibit the Cav1.2 (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc.

F-0401 is a calcium antagonist with platelet-activating factor receptor (PAFR) antagonistic action. F-0401 can be used for the research of neurological disease, such as stroke.

Onychocin B is a cyclic tetrapeptide isolated from Onychocola sclerotica. Onychocin B is a calcium channel blocker with an IC50 of 7.1 μM for Cav1.2.

TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and P2X2/3 receptors (IC50 = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC50 = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED50 = 6.35 µmol/kg)[1][2].

D-myo-Inositol-1,2,6-triphosphate (sodium) is one of the members in inositol phosphate family of second messengers that play an important role in transmitting cellular signals. D-myo-Inositol-1,2,6-triphosphate (sodium) can open calcium channels and increase intracellular calcium upon binding to its receptor on the endoplasmic reticulum.

8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose) sodium salt, a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR sodium salt reduces renal damage and the expression of caspase-3 and TRPM2.

D-myo-Inositol-2,3,5,6-tetraphosphate (2,3,5,6-IP4) tetrasodium is a inositol phosphate. D-myo-Inositol-2,3,5,6-tetraphosphate tetrasodium can be used for the study of calcium channels.

D-myo-Inositol-2,4,5-triphosphate (Ins(2,4,5)P3) (sodium salt) is a second messenger produced in cells by phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-biphosphate. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can open calcium channels and increase intracellular calcium upon binding to its receptors on the endoplasmic reticulum. D-myo-Inositol-2,4,5-triphosphate (sodium salt) also acts as a partial agonist at rat hepatic IP3 receptors. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can be studied in research on calcium ions signaling pathway.

BI-44847 is a selective SGLT2 inhibitor. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM).

D-myo-Inositol-1,2,4,5,6-pentaphosphate (Ins(1,2,4,5,6)P5) sodium salt is one of several different inositol oligophosphate isomers involved in signal transduction. In human Jurkat T lymphocytes, Ins(1,2,4,5,6)P5 (sodium salt) is phosphorylated to InsP6 by 1/3 kinase. D-myo-Inositol-1,2,4,5,6-pentaphosphate sodium salt is involved in calcium signaling.

HCA-6 is a calcium-channel and P-glycoprotein blocker. HCA-6 can induce cancer cells apoptosis and increase anticancer activity of Cisplatin. HCA-6 also exhibits antibacterial activity against Bacillus subtilis. HCA-6 can be used for the research of cancer and infection, such as breast cancer.

CP-283097 is a conformationally restricted and NR2B subtype-selective NMDA antagonist. CP-283097 efficiently competitively inhibits the binding of [³H]CP-101,606 to the rat meninges, with an IC50 value of 18 nM. CP-283097 exhibits nearly complete inhibition of the current mediated by the NR2B receptor (IC50 = 206 nM), while the inhibitory effect on the NR2A or NR2C receptors is very weak. CP-283097 demonstrates excellent central nervous system permeability and in vivo efficacy in animal models. CP-283097 can be used for neurological diseases related to excessive activation of NMDA receptors.

D-myo-inositol-1,2,3,5-tetraphosphate (Ins(1,2,3,5,6)-P5) tetrasodium is one of the Inositol phosphate isomers and can act as a soluble second messenger to participate in cellular calcium signaling.

D-myo-Inositol-1,2,4,5-tetraphosphate (DL-Ins-(1,2,4,5)P4) tetrasodium is raracemic regioisomer of myo-inositol tetrakisphosphates (IP4s). D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium is an Ins(1,4,5)P3 receptor agonist with a Ki of 11 nM. D-myo-Inositol-1,2,4,5-tetraphosphate tetrasodium induces Ca2+ mobilization with an EC50 value of 0.22 μM in CHO cells.

Glycerophosphoinositol 4,5-diphosphate (GroPI(4,5)P2) trisodium is a slowly metabolized analog of InsP3. Glycerophosphoinositol 4,5-diphosphate trisodium has an EC50 of 1.228 μM for inducing calcium release, with a degradation time constant of 13 seconds. Glycerophosphoinositol 4,5-diphosphate trisodium can be used to study the effect of InsP3 degradation on calcium signal recovery.

NIP-121 is a new type of potassium channel opener. NIP-121 significantly reduces mean pulmonary artery pressure and total pulmonary resistance through vasodilation. NIP-121 can be used for research on pulmonary arterial hypertension.

SGE-301 is a positive, allosteric NMDAR modulator. SGE-301 recovers NMDAR density and long-term potentiation to normal values. SGE-301 can be used in the research of neurological disorders.

CEB-1604 is an NMDA receptor antagonist. CEB-1604 inhibits NMDA-induced currents in oocytes transfected with NMDA receptor isoforms (NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D) with IC50 values ranging from 5 to 12 μM. CEB-1604 abolishes NMDA-dependent epileptiform discharges in rat cortical wedge preparations and reduces the depolarizing effects of NMDA. CEB-1604 can be used in the research field of neurological damage diseases.